Fangling Ning

机构：Binzhou Medical University, Shandong University of Aeronautics

发表论文 17 篇 · 总被引 180 次 · h-index 6

代表论文

• Single‐cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug‐resistance mechanisms of recurrent glioblastoma (2023 · Cancer Science · 被引 110)
• First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial (2025 · Journal of Thoracic Oncology · 被引 18)
• Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors. (2024 · Journal of Clinical Oncology · 被引 14)
• DARS-AS1 modulates cell proliferation and migration of gastric cancer cells by regulating miR-330-3p/NAT10 axis (2022 · Open Medicine · 被引 10)
• Efficacy and safety of XNW27011, a Claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with Claudin 18.2 positive gastric/gastroesophageal junction cancer: Results from ongoing phase I/II study. (2025 · Journal of Clinical Oncology · 被引 7)
• Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1/2 multicenter study. (2025 · Journal of Clinical Oncology · 被引 6)